IBDEI0HW ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8356,2)
 ;;=^271885
 ;;^UTILITY(U,$J,358.3,8357,0)
 ;;=682.2^^35^483^12
 ;;^UTILITY(U,$J,358.3,8357,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8357,1,4,0)
 ;;=4^682.2
 ;;^UTILITY(U,$J,358.3,8357,1,5,0)
 ;;=5^Cellulitis Of Trunk
 ;;^UTILITY(U,$J,358.3,8357,2)
 ;;=^271890
 ;;^UTILITY(U,$J,358.3,8358,0)
 ;;=070.1^^35^483^26
 ;;^UTILITY(U,$J,358.3,8358,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8358,1,4,0)
 ;;=4^070.1
 ;;^UTILITY(U,$J,358.3,8358,1,5,0)
 ;;=5^Hepatitis A 
 ;;^UTILITY(U,$J,358.3,8358,2)
 ;;=^126486
 ;;^UTILITY(U,$J,358.3,8359,0)
 ;;=070.30^^35^483^27
 ;;^UTILITY(U,$J,358.3,8359,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8359,1,4,0)
 ;;=4^070.30
 ;;^UTILITY(U,$J,358.3,8359,1,5,0)
 ;;=5^Hepatitis B, Acute
 ;;^UTILITY(U,$J,358.3,8359,2)
 ;;=^266626
 ;;^UTILITY(U,$J,358.3,8360,0)
 ;;=070.32^^35^483^28
 ;;^UTILITY(U,$J,358.3,8360,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8360,1,4,0)
 ;;=4^070.32
 ;;^UTILITY(U,$J,358.3,8360,1,5,0)
 ;;=5^Hepatitis B, Chronic
 ;;^UTILITY(U,$J,358.3,8360,2)
 ;;=^303249
 ;;^UTILITY(U,$J,358.3,8361,0)
 ;;=070.51^^35^483^29
 ;;^UTILITY(U,$J,358.3,8361,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8361,1,4,0)
 ;;=4^070.51
 ;;^UTILITY(U,$J,358.3,8361,1,5,0)
 ;;=5^Hepatitis C, Acute
 ;;^UTILITY(U,$J,358.3,8361,2)
 ;;=^266632
 ;;^UTILITY(U,$J,358.3,8362,0)
 ;;=070.54^^35^483^30
 ;;^UTILITY(U,$J,358.3,8362,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8362,1,4,0)
 ;;=4^070.54
 ;;^UTILITY(U,$J,358.3,8362,1,5,0)
 ;;=5^Hepatitis C, Chronic
 ;;^UTILITY(U,$J,358.3,8362,2)
 ;;=^303252
 ;;^UTILITY(U,$J,358.3,8363,0)
 ;;=571.41^^35^483^32
 ;;^UTILITY(U,$J,358.3,8363,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8363,1,4,0)
 ;;=4^571.41
 ;;^UTILITY(U,$J,358.3,8363,1,5,0)
 ;;=5^Hepatitis, Chronic Persist
 ;;^UTILITY(U,$J,358.3,8363,2)
 ;;=^259093
 ;;^UTILITY(U,$J,358.3,8364,0)
 ;;=571.1^^35^483^33
 ;;^UTILITY(U,$J,358.3,8364,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8364,1,4,0)
 ;;=4^571.1
 ;;^UTILITY(U,$J,358.3,8364,1,5,0)
 ;;=5^Hepatitis, ETOH acute
 ;;^UTILITY(U,$J,358.3,8364,2)
 ;;=^2597
 ;;^UTILITY(U,$J,358.3,8365,0)
 ;;=070.59^^35^483^34
 ;;^UTILITY(U,$J,358.3,8365,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8365,1,4,0)
 ;;=4^070.59
 ;;^UTILITY(U,$J,358.3,8365,1,5,0)
 ;;=5^Hepatitis, Other Viral
 ;;^UTILITY(U,$J,358.3,8365,2)
 ;;=Hepatitis, Other Viral^266631
 ;;^UTILITY(U,$J,358.3,8366,0)
 ;;=V08.^^35^483^24
 ;;^UTILITY(U,$J,358.3,8366,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8366,1,4,0)
 ;;=4^V08.
 ;;^UTILITY(U,$J,358.3,8366,1,5,0)
 ;;=5^HIV + Status (Asymptomatic)
 ;;^UTILITY(U,$J,358.3,8366,2)
 ;;=HIV + Status (Asymptomatic)^303392
 ;;^UTILITY(U,$J,358.3,8367,0)
 ;;=042.^^35^483^25
 ;;^UTILITY(U,$J,358.3,8367,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8367,1,4,0)
 ;;=4^042.
 ;;^UTILITY(U,$J,358.3,8367,1,5,0)
 ;;=5^HIV Disease (symptomatic)
 ;;^UTILITY(U,$J,358.3,8367,2)
 ;;=HIV Disease (symptomatic)^266500
 ;;^UTILITY(U,$J,358.3,8368,0)
 ;;=464.00^^35^483^2
 ;;^UTILITY(U,$J,358.3,8368,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8368,1,4,0)
 ;;=4^464.00
 ;;^UTILITY(U,$J,358.3,8368,1,5,0)
 ;;=5^Acute Laryngitis
 ;;^UTILITY(U,$J,358.3,8368,2)
 ;;=Acute Laryngitis^323469
 ;;^UTILITY(U,$J,358.3,8369,0)
 ;;=790.6^^35^483^1
 ;;^UTILITY(U,$J,358.3,8369,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8369,1,4,0)
 ;;=4^790.6
 ;;^UTILITY(U,$J,358.3,8369,1,5,0)
 ;;=5^Abnormal LFT's
 ;;^UTILITY(U,$J,358.3,8369,2)
 ;;=^87228
 ;;^UTILITY(U,$J,358.3,8370,0)
 ;;=780.60^^35^483^20
 ;;^UTILITY(U,$J,358.3,8370,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8370,1,4,0)
 ;;=4^780.60
 ;;
 ;;$END ROU IBDEI0HW
